Articles by " Jeff Stewart"
Filed Rate Doctrine Would Preempt California PUC
Summary The filed rate doctrine provides a strong basis for the argument that the California PUC’s action is preempted: if [...]
Fosamax Weekly: Merck Retains Exclusivity until 2018
April 30, 2003 INTRODUCTION Merck’s patent infringement suit against Teva came to trial in Wilmington, Delaware from March 4 to [...]
Fosamax® Daily: Appeals Court Will Rule for Merck
June 3, 2003 INTRODUCTION On June 3, 2003, the Court of Appeals for the Federal Circuit heard oral argument in [...]
Fosmax Daily: Merck will retain exclusivity until 2007
May 16, 2002 Introduction. Teva and IVAX’s legal efforts to launch a generic osteoporosis drug to compete with Merck’s Fosamax [...]
Fosmax: Courts Uphold Merck’s Daily & Weekly patents
(BUSINESS WIRE)–Oct. 30, 2003 Oct. 30, 2003–Merck & Co., Inc. announced today that the U.S. Court of Appeals for the [...]
FTC: Courts will approve Staples/Office Depot Merger
May 28, 1997 According to highly regarded anti-trust lawyers, there was no basis for the FTC action blocking the merger [...]
Grace reverse mergers failed to avoid asbestos liability
Reverse mergers with Grace cost Sealed Air $732 million & Fresenius $115 million in asbestos liabilities.
Great Lakes Chemical’s CEO Is a Whistleblower!!
Great Lakes Chemical (GLK) announced yesterday that the Justice Department had conditionally granted amnesty to it in the ongoing criminal [...]
Hatch Waxman Act #1
November 17, 1997 Introduction: Patent protection expired on Glaxo’s Zantac last July, and patents on Cardizam CD expire in 2002. [...]
Hatch Waxman Act #2
Introduction. Infringement by inducement is an important issue in the litigation involving Neurontin, Glaucoma, Prilosec, Buspar, Plavix and ribavarin. Because [...]
Related Case Type
